Developer docs
API playgroundTry for free, no card

Search company profiles

DiaMedica

Full company profile

uuid00037xh

Namestring
DiaMedica
Legal namestring
DiaMedica Therapeutics, Inc.
Websiteurl
diamedica.com
Company typeenum
Public
Founded yearint
2000
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ischemic stroke therapy, biopharmaceutical drug development, preeclampsia treatment, recombinant protein therapeutics, vascular disease treatments
Industry2 codes
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceuticals (Ischemic/Vascular Therapeutics)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development / Licensing Revenue
TypeLicensing Royalties
Description

DiaMedica is a pre-revenue clinical-stage biopharmaceutical company. All revenue potential is contingent on successful clinical development, regulatory approval, and commercialization of DM199. The company may pursue licensing agreements or co-development partnerships for commercialization. As of the available data, the company has no approved products and generates no product revenue.

diamedica.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1), as a novel therapeutic for three ischemic/vascular indications: preeclampsia (Phase 2), fetal growth restriction (Phase 2), and acute ischemic stroke via the Phase 2/3 ReMEDy2 trial. The drug acts through the kallikrein-kinin system to restore vascular health, reduce inflammation and oxidative stress, and is currently advancing in clinical trials with no approved products or product revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 25 mmHg systolic and 13 mmHg diastolic blood pressure reduction in preeclampsia proof-of-concept study; 13% statistically significant reduction in uterine artery resistance index
+3 more records
Product overview1 text field

DiaMedica is a clinical-stage biopharmaceutical company developing a single lead drug candidate, DM199 (rinvecalinase alfa), which is a recombinant form of human tissue kallikrein-1 (KLK1) protein. The company is advancing DM199 through multiple clinical programs including: (1) the Phase 2/3 ReMEDy2 trial for acute ischemic stroke, (2) Phase 2 trials for preeclampsia, and (3) Phase 2 trials for fetal growth restriction. The drug candidate works by restoring vascular health and function through vasodilation and reducing inflammation and oxidative stress.

Product and service3 records
1DM199 (rinvecalinase alfa) for Acute Ischemic Stroke — ReMEDy2 Phase 2/3 Trial
CategoryClinical-stage biologic for acute ischemic stroke
Description

Recombinant human tissue kallikrein-1 (rhKLK1) protein administered to acute ischemic stroke patients who are not candidates for tPA or mechanical thrombectomy, with the goal of enhancing collateral blood flow to reduce ischemic injury. Being studied in the Phase 2/3 ReMEDy2 trial at ~70 activated sites across the U.S., Canada, U.K., and Europe.

2DM199 (rinvecalinase alfa) for Preeclampsia — Phase 2 Trial
CategoryClinical-stage biologic for preeclampsia
Description

Subcutaneous DM199 (rinvecalinase alfa) being evaluated in a Phase 2 open-label, dose-ranging trial for early-onset preeclampsia in pregnant women between 24 and 32 weeks gestation, with the goal of stabilizing blood pressure and reducing uterine artery resistance without crossing the placental barrier.

3DM199 (rinvecalinase alfa) for Fetal Growth Restriction — Phase 2 Trial
CategoryClinical-stage biologic for fetal growth restriction
Description

Subcutaneous DM199 (rinvecalinase alfa) under evaluation in a Phase 2 trial in pregnant women with early-onset fetal growth restriction (27–32 weeks gestation), targeting up to 30 patients with the goal of improving placental blood flow and fetal growth outcomes.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeGTM or Marketing Partner
Description

DiaMedica presented at the Jefferies Global Healthcare Conference in June 2026 (New York), conducting fireside chats and company presentations. The company participates in multiple healthcare investor conferences for investor engagement and capital markets visibility.

Strategic tierMinorTypeGTM or Marketing Partner
Description

DiaMedica participated in TD Cowen's 46th Annual Healthcare Conference in Boston (March 2026) for investor relations and visibility among institutional investors and analysts.

Strategic tierMinorTypeGTM or Marketing Partner
Description

DiaMedica participated in Barclays' 28th Annual Global Healthcare Conference in Miami (March 2026) for investor engagement and company presentations.

Strategic tierMinorTypeGTM or Marketing Partner
Description

DiaMedica participated in Leerink Partners' Global Healthcare Conference in Miami (March 2026) for fireside chats and one-on-one meetings with investors.

Strategic tierMinorTypeGTM or Marketing Partner
Description

CEO Rick Pauls presented at the RedChip Biotech Investor Conference (April 2026), highlighting clinical data for DM199 in preeclampsia and acute ischemic stroke programs, and discussing upcoming stroke trial interim analysis catalyst.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Privately-held clinical-stage biotech developing nerinetide (NA-1), a neuroprotectant for acute ischemic stroke. Directly comparable to DM199 as a non-thrombolytic biologic targeting the same large unmet need of stroke patients ineligible for tPA/thrombectomy.

TypeBroad incumbent
Description

Large medical device company with leading mechanical thrombectomy portfolio (Trevo) for ischemic stroke. Represents the dominant non-pharmacologic alternative to DM199 in the stroke treatment landscape.

3Athersys
TypeDirect peer
Description

Clinical-stage biotech developing MultiStem cell therapy for ischemic stroke (MASTERS-2 trial). Closely comparable to DiaMedica as a small-cap clinical-stage stroke biotech with multi-asset pipeline and similar capital constraints.

TypeDirect peer
Description

Clinical-stage cell therapy company developing CTX stem cell therapy for stroke disability. Comparable as a small-cap, clinical-stage biotech pursuing novel biologic mechanisms for ischemic stroke.

TypeBroad incumbent
Description

Global pharmaceutical company that distributes Actilyse (alteplase) internationally for acute ischemic stroke treatment. Provides incumbent competitive reference and global commercialization benchmark for DM199's potential stroke launch.

TypeDirect peer
Description

Clinical-stage biotech developing 3K3A-APC, a recombinant protein therapeutic for acute ischemic stroke. Closely comparable to DM199 as a recombinant biologic protein in stroke with similar mechanism-of-action profile targeting vascular/neuroprotective pathways.

TypeBroad incumbent
Description

Diversified medical device leader with neurovascular portfolio including stroke treatment technologies acquired from Covidien. Represents a key strategic competitor and potential acquirer in the stroke space.

TypeBroad incumbent
Description

Medical device company specializing in stroke thrombectomy systems (Indigo, Lightning). Comparable as an incumbent in the acute ischemic stroke treatment market where DM199 would compete.

TypeEmerging player
Description

Clinical-stage biotech developing siRNA therapy (CMP-CPS-001) for preeclampsia. Direct emerging competitor to DiaMedica's preeclampsia program targeting the same orphan indication with no approved therapies.

10Biogen
TypeBroad incumbent
Description

Major biopharmaceutical company that markets Activase (alteplase), the standard thrombolytic for acute ischemic stroke. Provides incumbent competitive context for DM199 in the stroke treatment paradigm.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DiaMedica

Clinical-Stage Biopharmaceuticals (Ischemic/Vascular Therapeutics)diamedica.com

DiaMedica firmographics

Firmographics
Name
DiaMedica
Legal name
DiaMedica Therapeutics, Inc.
Website
https://diamedica.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

DiaMedica industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals (Ischemic/Vascular Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Ischemic stroke therapy
  • Biopharmaceutical drug development
  • Preeclampsia treatment
  • Recombinant protein therapeutics
  • Vascular disease treatments

Where DiaMedica is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DiaMedica business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development / Licensing Revenue: DiaMedica is a pre-revenue clinical-stage biopharmaceutical company. All revenue potential is contingent on successful clinical development, regulatory approval, and commercialization of DM199. The company may pursue licensing agreements or co-development partnerships for commercialization. As of the available data, the company has no approved products and generates no product revenue.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

DiaMedica product offering

Product offering

Core offering

DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1), as a novel therapeutic for three ischemic/vascular indications: preeclampsia (Phase 2), fetal growth restriction (Phase 2), and acute ischemic stroke via the Phase 2/3 ReMEDy2 trial. The drug acts through the kallikrein-kinin system to restore vascular health, reduce inflammation and oxidative stress, and is currently advancing in clinical trials with no approved products or product revenue.

Product overview

DiaMedica is a clinical-stage biopharmaceutical company developing a single lead drug candidate, DM199 (rinvecalinase alfa), which is a recombinant form of human tissue kallikrein-1 (KLK1) protein. The company is advancing DM199 through multiple clinical programs including: (1) the Phase 2/3 ReMEDy2 trial for acute ischemic stroke, (2) Phase 2 trials for preeclampsia, and (3) Phase 2 trials for fetal growth restriction. The drug candidate works by restoring vascular health and function through vasodilation and reducing inflammation and oxidative stress.

Differentiator

Problem solved

Functional benefit

Products and services

  • DM199 (rinvecalinase alfa) for Acute Ischemic Stroke — ReMEDy2 Phase 2/3 Trial Recombinant human tissue kallikrein-1 (rhKLK1) protein administered to acute ischemic stroke patients who are not candidates for tPA or mechanical thrombectomy, with the goal of enhancing collateral blood flow to reduce ischemic injury. Being studied in the Phase 2/3 ReMEDy2 trial at ~70 activated sites across the U.S., Canada, U.K., and Europe.
  • DM199 (rinvecalinase alfa) for Preeclampsia — Phase 2 Trial Subcutaneous DM199 (rinvecalinase alfa) being evaluated in a Phase 2 open-label, dose-ranging trial for early-onset preeclampsia in pregnant women between 24 and 32 weeks gestation, with the goal of stabilizing blood pressure and reducing uterine artery resistance without crossing the placental barrier.
  • DM199 (rinvecalinase alfa) for Fetal Growth Restriction — Phase 2 Trial Subcutaneous DM199 (rinvecalinase alfa) under evaluation in a Phase 2 trial in pregnant women with early-onset fetal growth restriction (27–32 weeks gestation), targeting up to 30 patients with the goal of improving placental blood flow and fetal growth outcomes.

Quantifiable outcome

  • 25 mmHg systolic and 13 mmHg diastolic blood pressure reduction in preeclampsia proof-of-concept study; 13% statistically significant reduction in uterine artery resistance index
  • +3 more outcomes

Companies that use DiaMedica

Customer profile

Segments3 records

Ideal customer profiles3 records

DiaMedica technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

DiaMedica partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor.

  • Jefferies Global Healthcare ConferenceminorGTM or Marketing PartnerDiaMedica presented at the Jefferies Global Healthcare Conference in June 2026 (New York), conducting fireside chats and company presentations. The company participates in multiple healthcare investor conferences for investor engagement and capital markets visibility.
  • TD Cowen Annual Healthcare ConferenceminorGTM or Marketing PartnerDiaMedica participated in TD Cowen's 46th Annual Healthcare Conference in Boston (March 2026) for investor relations and visibility among institutional investors and analysts.
  • Barclays Global Healthcare ConferenceminorGTM or Marketing PartnerDiaMedica participated in Barclays' 28th Annual Global Healthcare Conference in Miami (March 2026) for investor engagement and company presentations.
  • Leerink Partners Global Healthcare ConferenceminorGTM or Marketing PartnerDiaMedica participated in Leerink Partners' Global Healthcare Conference in Miami (March 2026) for fireside chats and one-on-one meetings with investors.
  • RedChip Biotech Investor ConferenceminorGTM or Marketing PartnerCEO Rick Pauls presented at the RedChip Biotech Investor Conference (April 2026), highlighting clinical data for DM199 in preeclampsia and acute ischemic stroke programs, and discussing upcoming stroke trial interim analysis catalyst.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

DiaMedica competitors and assessment

Company assessment

Direct peers

  • NoNO Inc. Privately-held clinical-stage biotech developing nerinetide (NA-1), a neuroprotectant for acute ischemic stroke. Directly comparable to DM199 as a non-thrombolytic biologic targeting the same large unmet need of stroke patients ineligible for tPA/thrombectomy.
  • Athersys: Clinical-stage biotech developing MultiStem cell therapy for ischemic stroke (MASTERS-2 trial). Closely comparable to DiaMedica as a small-cap clinical-stage stroke biotech with multi-asset pipeline and similar capital constraints.
  • ReNeuron Group: Clinical-stage cell therapy company developing CTX stem cell therapy for stroke disability. Comparable as a small-cap, clinical-stage biotech pursuing novel biologic mechanisms for ischemic stroke.
  • ZZ Biotech: Clinical-stage biotech developing 3K3A-APC, a recombinant protein therapeutic for acute ischemic stroke. Closely comparable to DM199 as a recombinant biologic protein in stroke with similar mechanism-of-action profile targeting vascular/neuroprotective pathways.

Broad incumbents

  • Stryker: Large medical device company with leading mechanical thrombectomy portfolio (Trevo) for ischemic stroke. Represents the dominant non-pharmacologic alternative to DM199 in the stroke treatment landscape.
  • Roche: Global pharmaceutical company that distributes Actilyse (alteplase) internationally for acute ischemic stroke treatment. Provides incumbent competitive reference and global commercialization benchmark for DM199's potential stroke launch.
  • Medtronic: Diversified medical device leader with neurovascular portfolio including stroke treatment technologies acquired from Covidien. Represents a key strategic competitor and potential acquirer in the stroke space.
  • Penumbra: Medical device company specializing in stroke thrombectomy systems (Indigo, Lightning). Comparable as an incumbent in the acute ischemic stroke treatment market where DM199 would compete.
  • Biogen: Major biopharmaceutical company that markets Activase (alteplase), the standard thrombolytic for acute ischemic stroke. Provides incumbent competitive context for DM199 in the stroke treatment paradigm.

Emerging players

  • Comanche Biopharma: Clinical-stage biotech developing siRNA therapy (CMP-CPS-001) for preeclampsia. Direct emerging competitor to DiaMedica's preeclampsia program targeting the same orphan indication with no approved therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

DiaMedica social profiles

Digital presence

DiaMedica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DiaMedica leadership team

Management profile

Number of profiles

Profiles9 records

DiaMedica funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DiaMedica M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiaMedica

What does DiaMedica do?

DiaMedica is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1), as a novel therapeutic for three ischemic/vascular indications: preeclampsia (Phase 2), fetal growth restriction (Phase 2), and acute ischemic stroke via the Phase 2/3 ReMEDy2 trial. The drug acts through the kallikrein-kinin system to restore vascular health, reduce inflammation and oxidative stress, and is currently advancing in clinical trials with no approved products or product revenue.

Is DiaMedica a public or private company?

DiaMedica is a public company. It is classified as public and is currently operating.

When was DiaMedica founded?

DiaMedica was founded in 2000. It employs 11 to 50 people.

Where is DiaMedica based?

DiaMedica is headquartered in Minneapolis, United States, in the North America region.

How does DiaMedica make money?

One revenue line is on record: drug Development / Licensing Revenue.

Who are DiaMedica's main competitors?

Direct peers on record are NoNO Inc., Athersys, ReNeuron Group and ZZ Biotech. Broad incumbents are Stryker, Roche, Medtronic, Penumbra and Biogen. Comanche Biopharma is listed as an emerging player.

Does DiaMedica have an API?

No public API is recorded for DiaMedica.

What industry is DiaMedica in?

DiaMedica's product category is Clinical-Stage Biopharmaceuticals (Ischemic/Vascular Therapeutics). Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StDiaMedica Therapeutics Insiders Land Bargain With Gains Of US$2.1mInsiders bought $14m of DiaMedica Therapeutics shares over the past year, with Jan Stahlberg purchasing $7.6m at $8.57 per share. The shares are now worth $16.1m after a 14% drop, and insiders own 47% of the company.Seeking AlphaDiaMedica Therapeutics: Maintaining "Buy" DM199 FGR Data November 2026 And AIS AdvancementDiaMedica Therapeutics maintains a Buy rating on DM199, with a Q1 2027 interim analysis for the ReMEDy2 stroke trial and a November 24, 2026 fetal growth restriction update. European and Canadian preeclampsia trials are authorized, while the U.S. trial depends on toxicity data and an IND filing.Seeking AlphaDiaMedica Therapeutics Inc. (DMAC) Q3 2026 Earnings Call TranscriptDiaMedica Therapeutics reported Q3 2026 earnings, citing two clinical milestones: completion of enrollment in the first two cohorts of a Phase II fetal growth restriction study and enrollment of 200 participants in ReMEDy2. The company also noted that enrollment in ReMEDy2 was completed in October.TradingViewDMAC: Clinical milestones advanced, with cash runway projected into Q4 2027DiaMedica Therapeutics reported that ReMEDy2 reached its interim-analysis enrollment threshold and FGR cohorts completed enrollment, with the DSMB review expected in Q1 2027. The company projects $34.9M in cash to fund operations into Q4 2027.Business Wire BlogDiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsDiaMedica Therapeutics reported Q3 2026 financial results, with cash of $34.9 million and net losses of $11.3 million for the quarter. The company completed enrollment in the first two cohorts of its Phase 2 FGR trial and reached the 200-participant threshold for the ReMEDy2 stroke trial interim analysis, expected in Q1 2027.Quiver QuantitativeDiaMedica Reports $11.3 Million Third-Quarter Net Loss as ReMEDy2 Tops 200 Enrollments | DMAC Stock NewsDiaMedica Therapeutics reported a Q3 2026 net loss of $11.3 million, down from $8.6 million a year earlier, with cash of $34.9 million. The company completed enrollment in two FGR trial cohorts and said ReMEDy2 surpassed 200 participants, enabling an interim analysis after the 200th participant completes 90-day follow-up.Stock TitanDiaMedica Q3 earnings: net loss rises to $11.3MDiaMedica Therapeutics reported a Q3 2026 net loss of $11.3 million, up from $8.6 million in Q3 2025. The company completed enrollment in the first two cohorts of its Phase 2 early-onset fetal growth restriction trial and reached the 200-participant threshold for the ReMEDy2 stroke trial interim analysis. It will present preliminary FGR results at a November 24 KOL event.Business Wire BlogDiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026DiaMedica Therapeutics will report its third quarter 2026 financial results after market close on November 12, 2026, and host a live conference call on November 13 at 8:00 AM Eastern Time. The company, focused on preeclampsia, fetal growth restriction, and acute ischemic stroke, will discuss results and provide a business update.YahooDiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026DiaMedica Therapeutics will report its third quarter 2026 financial results after market close on November 12, 2026, and host a live conference call on November 13 at 8:00 AM Eastern Time. The call will provide a business update and discuss the results.FinancialContent Business PageDiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026DiaMedica Therapeutics will report its third quarter 2026 financial results after markets close on November 12, 2026, and host a live conference call on November 13 at 8:00 AM Eastern Time. The call will provide a business update and discuss the results.